Description
GNF-2 is an inhibitor of Abl kinase that exhibits anticancer chemotherapeutic, anti-resorptive, and anti-osteoporotic activities. GNF-2 shows potential benefit in the treatment of Philadelphia chromosome-positive acute myelogenous leukemia (ALL). In vitro, GNF-2 inhibits differentiation of osteoclasts, activity of NF-κB, and induction of c-Fos and NFATc1, resulting in caspase-mediated apoptosis. GNF-2 also inhibits resorption of mature osteoclasts and prevents phagocytosis in bone marrow-derived macrophages. In vivo, this compound decreases osteoclast numbers and prevents bone loss.
References
Kim HJ, Yoon HJ, Choi JY, et al. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity. J Leukoc Biol. 2014 Feb;95(2):337-45. PMID: 24130113.
Greuber EK, Pendergast AM. Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages. J Immunol. 2012 Dec 1;189(11):5382-92. PMID: 23100514.
Mian AA, Metodieva A, Najajreh Y, et al. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica. 2012 Feb;97(2):251-7. PMID: 22058195.
Deng X, Okram B, Ding Q, et al. Expanding the diversity of allosteric bcr-abl inhibitors. J Med Chem. 2010 Oct 14;53(19):6934-46. PMID: 20828158.
Adrián FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006 Feb;2(2):95-102. PMID: 16415863.
